The pharmacogenomics of statins

Pharmacological Research

Volumn 88, Issue , 2014, Pages 99-106

  Gelissen, Ingrid C ^a   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Drug metabolism; Drug transport; LDL cholesterol; Pharmacogenomics; Statins

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER; PHARMACOLOGICAL BIOMARKER; SLCO1B1 PROTEIN, HUMAN;

ABCB1 GENE; ABCG2 GENE; APOLIPOPROTEIN C1 GENE; APOLIPOPROTEIN C2 GENE; APOLIPOPROTEIN E GENE; CHOLESTEROL METABOLISM; CYP2C9 GENE; CYP3A4 GENE; CYP3A5 GENE; CYP7A1 GENE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; GENE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE GENE; KIF6 GENE; LIPOPROTEIN A GENE; LOW DENSITY LIPOPROTEIN RECEPTOR GENE; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE; GENETICS;

BIOMARKERS, PHARMACOLOGICAL; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS;

EID: 84906791063     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.12.002     Document Type: Review

References (96)

1. C.M. Minder, R.S. Blumenthal, and M.J. Blaha Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks Curr Opin Cardiol 28 5 2013 554 560
2. J. Beltowski, G. Wojcicka, and A. Jamroz-Wisniewska Adverse effects of statins - mechanisms and consequences Curr Drug Saf 4 3 2009 209 228
3. Y.S. Chatzizisis, K.C. Koskinas, G. Misirli, C. Vaklavas, A. Hatzitolios, and G.D. Giannoglou Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment Drug Saf 33 3 2010 171 187
4. M.A. Giorgi, C. Caroli, H.C. Arazi, and G. Di Girolamo Pharmacogenomics and adverse drug reactions: the case of statins Expert Opin Pharmacother 12 10 2011 1499 1509
5. M.K. Degorter, R.G. Tirona, U.I. Schwarz, Y.H. Choi, G.K. Dresser, and N. Suskin et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care Circ Cardiovasc Genet 6 4 2013 400 408
6. J.J. Verschuren, S. Trompet, J.A. Wessels, H.J. Guchelaar, M.P. de Maat, and M.L. Simoons et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 33 2 2012 165 175
7. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 1 2005 117 125 (Pubitemid 40204354)
8. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 1 2006 71 105 (Pubitemid 44301483)
9. K. Kurose, E. Sugiyama, and Y. Saito Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development Drug Metab Pharmacokinet 27 1 2012 9 54
10. Y. Shitara, K. Maeda, K. Ikejiri, K. Yoshida, T. Horie, and Y. Sugiyama Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption Biopharm Drug Dispos 34 1 2013 45 78
11. M.K. Pasanen, P.J. Neuvonen, and M. Niemi Global analysis of genetic variation in SLCO1B1 Pharmacogenomics 9 1 2008 19 33 (Pubitemid 351560529)
12. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 15 7 2005 513 522 (Pubitemid 41017600)
13. M.K. Pasanen, M. Neuvonen, P.J. Neuvonen, and M. Niemi SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet Genomics 16 12 2006 873 879 (Pubitemid 44772805)
14. M.K. Pasanen, H. Fredrikson, P.J. Neuvonen, and M. Niemi Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 82 6 2007 726 733 (Pubitemid 350114817)
15. C.I. Choi, Y.J. Lee, H.I. Lee, B.H. Kim, M.J. Kim, and C.G. Jang et al. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin Xenobiotica 42 5 2012 496 501
16. J.H. Choi, M.G. Lee, J.Y. Cho, J.E. Lee, K.H. Kim, and K. Park Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans Clin Pharmacol Ther 83 2 2008 251 257 (Pubitemid 351147710)
17. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, and F. Matsuda et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 8 2008 789 799
18. D. Voora, S.H. Shah, I. Spasojevic, S. Ali, C.R. Reed, and B.A. Salisbury et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 17 2009 1609 1616
19. R.A. Wilke, L.B. Ramsey, S.G. Johnson, W.D. Maxwell, H.L. McLeod, and D. Voora et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy Clin Pharmacol Ther 92 1 2012 112 117
20. L.A. Donnelly, A.S. Doney, R. Tavendale, C.C. Lang, E.R. Pearson, and H.M. Colhoun et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study Clin Pharmacol Ther 89 2 2011 210 216
21. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, and C. Kyrklund et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 7 2004 429 440 (Pubitemid 38971233)
22. K. Maeda, I. Ieiri, K. Yasuda, A. Fujino, H. Fujiwara, and K. Otsubo et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril Clin Pharmacol Ther 79 5 2006 427 439
23. J. Wen, and Y. Xiong OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers J Clin Pharm Ther 35 1 2010 99 104
24. M. Hu, V.W. Mak, O.Q. Yin, T.T. Chu, and B. Tomlinson Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin Drug Metab Pharmacokinet 28 2 2013 104 108
25. I.D. Kerr, A.J. Haider, and I.C. Gelissen The ABCG family of membrane-associated transporters: you don't have to be big to be mighty Br J Pharmacol 164 7 2011 1767 1779
26. R.W. Robey, K.K. To, O. Polgar, M. Dohse, P. Fetsch, and M. Dean et al. ABCG2: a perspective Adv Drug Deliv Rev 61 1 2009 3 13
27. K. Morisaki, R.W. Robey, C. Ozvegy-Laczka, Y. Honjo, O. Polgar, and K. Steadman et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2 Cancer Chemother Pharmacol 56 2 2005 161 172 (Pubitemid 40884271)
28. R. Elsby, C. Hilgendorf, and K. Fenner Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1 Clin Pharmacol Ther 92 5 2012 584 598
29. B. Tomlinson, M. Hu, V.W. Lee, S.S. Lui, T.T. Chu, and E.W. Poon et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin Clin Pharmacol Ther 87 5 2010 558 562
30. N. Mirosevic Skvrce, N. Bozina, L. Zibar, I. Barisic, L. Pejnovic, and V. Macolic Sarinic CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study Pharmacogenomics 14 12 2013 1419 1431
31. R. Callaghan, E. Crowley, S. Potter, and I.D. Kerr P-glycoprotein: so many ways to turn it on J Clin Pharmacol 48 3 2008 365 378
32. J.E. Keskitalo, K.J. Kurkinen, P.J. Neuvoneni, and M. Niemi ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin Clin Pharmacol Ther 84 4 2008 457 461
33. J.E. Keskitalo, K.J. Kurkinen, M. Neuvonen, J.T. Backman, P.J. Neuvonen, and M. Niemi No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin Br J Clin Pharmacol 68 2 2009 207 213
34. M. Fiegenbaum, F.R. da Silveira, C.R. Van der Sand, L.C. Van der Sand, M.E. Ferreira, and R.C. Pires et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment Clin Pharmacol Ther 78 5 2005 551 558 (Pubitemid 41698910)
35. L.M. Hodges, S.M. Markova, L.W. Chinn, J.M. Gow, D.L. Kroetz, and T.E. Klein et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein) Pharmacogenet Genomics 21 3 2011 152 161
36. D. Wang, A.D. Johnson, A.C. Papp, D.L. Kroetz, and W. Sadee Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability Pharmacogenet Genomics 15 10 2005 693 704 (Pubitemid 41345321)
37. C. Kimchi-Sarfaty, J.M. Oh, I.W. Kim, Z.E. Sauna, A.M. Calcagno, and S.V. Ambudkar et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 5811 2007 525 528 (Pubitemid 46175758)
38. J.L. Mega, D.A. Morrow, A. Brown, C.P. Cannon, and M.S. Sabatine Identification of genetic variants associated with response to statin therapy Arterioscler Thromb Vasc Biol 29 9 2009 1310 1315
39. J.F. Thompson, M. Man, K.J. Johnson, L.S. Wood, M.E. Lira, and D.B. Lloyd et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response Pharmacogenomics J 5 6 2005 352 358
40. A.J. McLachlan, S.N. Hilmer, and D.G. Le Couteur Variability in response to medicines in older people: phenotypic and genotypic factors Clin Pharmacol Ther 85 4 2009 431 433
41. S.D. Maggo, M.A. Kennedy, and D.W. Clark Clinical implications of pharmacogenetic variation on the effects of statins Drug Saf 34 1 2011 1 19
42. C.D. Scripture, and J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin Pharmacokinet 40 4 2001 263 281 (Pubitemid 32458153)
43. J. Kirchheiner, D. Kudlicz, C. Meisel, S. Bauer, I. Meineke, and I. Roots et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers Clin Pharmacol Ther 74 2 2003 186 194 (Pubitemid 36951816)
44. H. Buzkova, K. Pechandova, V. Danzig, T. Vareka, F. Perlik, and A. Zak et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population Med Sci Monit 18 8 2012 CR512 CR517
45. H. Fujino, T. Saito, Y. Tsunenari, and J. Kojima Effect of gemfibrozil on the metabolism of pitavastatin - determining the best animal model for human CYP and UGT activities Drug Metabol Drug Interact 20 1-2 2004 25 42 (Pubitemid 38943446)
46. H.K. Lee, M. Hu, S. Lui, C.S. Ho, C.K. Wong, and B. Tomlinson Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients Pharmacogenomics 14 11 2013 1283 1294
47. L. Elens, T. van Gelder, D.A. Hesselink, V. Haufroid, and R.H. van Schaik CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy Pharmacogenomics 14 1 2013 47 62
48. J. Lamba, J.M. Hebert, E.G. Schuetz, T.E. Klein, and R.B. Altman PharmGKB summary: very important pharmacogene information for CYP3A5 Pharmacogenet Genomics 22 7 2012 555 558
49. J. Shin, D.F. Pauly, M.A. Pacanowski, T. Langaee, R.F. Frye, and J.A. Johnson Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin Pharmacotherapy 31 10 2011 942 950
50. K.T. Kivisto, M. Niemi, E. Schaeffeler, K. Pitkala, R. Tilvis, and M.F. Fromm et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 14 8 2004 523 525 (Pubitemid 39100004)
51. E.B. Daily, and C.L. Aquilante Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies Pharmacogenomics 10 9 2009 1489 1510
52. A.B. Mulder, H.J. van Lijf, M.A. Bon, F.A. van den Bergh, D.J. Touw, and C. Neef et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Clin Pharmacol Ther 70 6 2001 546 551 (Pubitemid 34008412)
53. P. Zuccaro, G. Mombelli, L. Calabresi, D. Baldassarre, I. Palmi, and C.R. Sirtori Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin Pharmacol Res 55 4 2007 310 317 (Pubitemid 46518161)
54. J. Geisel, K.T. Kivisto, E.U. Griese, and M. Eichelbaum The efficacy of simvastatin is not influenced by CYP2D6 polymorphism Clin Pharmacol Ther 72 5 2002 595 596 (Pubitemid 36237731)
55. O.Q. Yin, V.W. Mak, M. Hu, B.S. Fok, M.S. Chow, and B. Tomlinson Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects Eur J Clin Pharmacol 68 6 2012 943 949
56. S. Marusic, A. Lisicic, I. Horvatic, V. Bacic-Vrca, and N. Bozina Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction Int J Clin Pharm 34 6 2012 825 827
57. W. Sadee Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: statins, SLCO1B1, and CYP3A4 as an example J Pharm Sci 102 9 2013 2924 2929
58. A. Endo The discovery and development of HMG-CoA reductase inhibitors J Lipid Res 33 11 1992 1569 1582
59. J.L. Goldstein, and M.S. Brown The LDL receptor Arterioscler Thromb Vasc Biol 29 4 2009 431 438
60. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 5519 2001 1160 1164 (Pubitemid 32440937)
61. D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr., and P.M. Ridker Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 23 2004 2821 2827 (Pubitemid 38747801)
62. L.A. Donnelly, A.S. Doney, J. Dannfald, A.L. Whitley, C.C. Lang, and A.D. Morris et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study Pharmacogenet Genomics 18 12 2008 1021 1026
63. R.M. Krauss, L.M. Mangravite, J.D. Smith, M.W. Medina, D. Wang, and X. Guo et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment Circulation 117 12 2008 1537 1544 (Pubitemid 351440642)
64. M.W. Medina, F. Gao, W. Ruan, J.I. Rotter, and R.M. Krauss Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin Circulation 118 4 2008 355 362
65. J.Y. Chung, S.K. Cho, E.S. Oh, D.H. Lee, L.A. Lim, and S.B. Jang et al. Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects J Clin Pharmacol 52 3 2012 339 346
66. J.F. Thompson, C.L. Hyde, L.S. Wood, S.A. Paciga, D.A. Hinds, and D.R. Cox et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort Circ Cardiovasc Genet 2 2 2009 173 181
67. R. Burkhardt, E.E. Kenny, J.K. Lowe, A. Birkeland, R. Josowitz, and M. Noel et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13 Arterioscler Thromb Vasc Biol 28 11 2008 2078 2084
68. C.Y. Yu, E. Theusch, K. Lo, L.M. Mangravite, D. Naidoo, and M. Kutilova et al. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism Hum Mol Genet 2013 10.1093/hmg/ddt422 [Epub ahead of print]
69. Y.C. Chen, Y.D. Chen, X. Li, W. Post, D. Herrington, and J.F. Polak et al. The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis Lipids 44 8 2009 733 743
70. L.M. Mangravite, M.W. Medina, J. Cui, S. Pressman, J.D. Smith, and M.J. Rieder et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin Arterioscler Thromb Vasc Biol 30 7 2010 1485 1492
71. Y. Lu, E.J. Feskens, J.M. Boer, S. Imholz, W.M. Verschuren, and C. Wijmenga et al. Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study Atherosclerosis 213 1 2010 200 205
72. D.I. Chasman, F. Guilianini, J. MacFadyen, B.J. Barratt, F. Nyberg, and P.M. Ridker Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial Circ Cardiovasc Genet 5 2012 257 264
73. H. Zhu, H.M. Tucker, K.E. Grear, J.F. Simpson, A.K. Manning, and L.A. Cupples et al. A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol Hum Mol Genet 16 14 2007 1765 1772 (Pubitemid 47241835)
74. F. Gao, H.E. Ihn, M.W. Medina, and R.M. Krauss A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function Hum Mol Genet 22 7 2013 1424 1431
75. M.W. Medina, F. Gao, D. Naidoo, L.L. Rudel, R.E. Temel, and A.L. McDaniel et al. Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake PLoS ONE 6 4 2011 e19420
76. B.J. Peters, H. Pett, O.H. Klungel, B.H. Stricker, B.M. Psaty, and N.L. Glazer et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI Atherosclerosis 217 2 2011 458 464
77. P. Yue, M. Averna, X. Lin, and G. Schonfeld The c.43-44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population Hum Mutat 27 5 2006 460 466
78. L. Pisciotta, R. Sallo, C. Rabacchi, A. Wunsch, S. Calandra, and S. Bertolini Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia Nutr Metab Cardiovasc Dis 22 10 2012 831 835
79. V. Sorrentino, and N. Zelcer Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor Curr Opin Lipidol 23 3 2012 213 219
80. D. Shiffman, E.S. O'Meara, L.A. Bare, C.M. Rowland, J.Z. Louie, and A.R. Arellano et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 28 1 2008 173 179
81. O.A. Iakoubova, C.H. Tong, C.M. Rowland, T.G. Kirchgessner, B.A. Young, and A.R. Arellano et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials J Am Coll Cardiol 51 4 2008 435 443
82. O.A. Iakoubova, M.S. Sabatine, C.M. Rowland, C.H. Tong, J.J. Catanese, and K. Ranade et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol 51 4 2008 449 455
83. M.M. Hoffmann, W. Marz, B. Genser, C. Drechsler, and C. Wanner Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study Atherosclerosis 219 2 2011 659 662
84. H. Akao, E. Polisecki, K. Kajinami, S. Trompet, M. Robertson, and I. Ford et al. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly Atherosclerosis 220 2 2012 456 462
85. T.L. Assimes, H. Holm, S. Kathiresan, M.P. Reilly, G. Thorleifsson, and B.F. Voight et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies J Am Coll Cardiol 56 19 2010 1552 1563
86. P. Peng, J. Lian, R.S. Huang, L. Xu, Y. Huang, and Y. Ba et al. Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect PLoS ONE 7 12 2012 e50126
87. S.L. Charland, B.C. Agatep, V. Herrera, B. Schrader, F.W. Frueh, and M. Ryvkin et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial Pharmacogenomics J 2013
88. S. Trompet, A.J. de Craen, I. Postmus, I. Ford, N. Sattar, and M. Caslake et al. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses BMC Med Genet 12 2011 131
89. M.J. Barber, L.M. Mangravite, C.L. Hyde, D.I. Chasman, J.D. Smith, and C.A. McCarty et al. Genome-wide association of lipid-lowering response to statins in combined study populations PLoS ONE 5 3 2010 e9763
90. H.A. Deshmukh, H.M. Colhoun, T. Johnson, P.M. McKeigue, D.J. Betteridge, and P.N. Durrington et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) J Lipid Res 53 5 2012 1000 1011
91. L.A. Donnelly, N.R. van Zuydam, K. Zhou, R. Tavendale, F. Carr, and A.H. Maitland-van der Zee et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment Pharmacogenet Genomics 23 10 2013 518 525
92. J.C. Hopewell, S. Parish, A. Offer, E. Link, R. Clarke, and M. Lathrop et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study Eur Heart J 34 13 2013 982 992
93. Y. Li, M.M. Luke, D. Shiffman, and J.J. Devlin Genetic variants in the apolipoprotein(a) gene and coronary heart disease Circ Cardiovasc Genet 4 5 2011 565 573
94. X.Y. Jiang, Q. Zhang, P. Chen, S.Y. Li, N.N. Zhang, and X.D. Chen et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin J Clin Pharm Ther 37 6 2012 719 723
95. M.J. Sorich, M.D. Wiese, R.L. O'Shea, and B. Pekarsky Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia Pharmacoeconomics 31 5 2013 377 391
96. P.J. Neuvonen, J.T. Backman, and M. Niemi Pharmacokinetic comparison of the potential over-the-counter statins lovastatin, fluvastatin and pravastatin Clin Pharmacokinet 47 7 2008 463 474 (Pubitemid 351861958)